AU2001232245A1 - Tnf- alpha inhibitors - Google Patents
Tnf- alpha inhibitorsInfo
- Publication number
- AU2001232245A1 AU2001232245A1 AU2001232245A AU3224501A AU2001232245A1 AU 2001232245 A1 AU2001232245 A1 AU 2001232245A1 AU 2001232245 A AU2001232245 A AU 2001232245A AU 3224501 A AU3224501 A AU 3224501A AU 2001232245 A1 AU2001232245 A1 AU 2001232245A1
- Authority
- AU
- Australia
- Prior art keywords
- tnf
- alpha inhibitors
- inhibitors
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-38266 | 2000-02-10 | ||
JP2000038266 | 2000-02-10 | ||
PCT/JP2001/000881 WO2001058443A1 (en) | 2000-02-10 | 2001-02-08 | TNF- α INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001232245A1 true AU2001232245A1 (en) | 2001-08-20 |
Family
ID=18562028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001232245A Abandoned AU2001232245A1 (en) | 2000-02-10 | 2001-02-08 | Tnf- alpha inhibitors |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030018040A1 (en) |
EP (1) | EP1275388A4 (en) |
AU (1) | AU2001232245A1 (en) |
CA (1) | CA2399396A1 (en) |
WO (1) | WO2001058443A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4239592B2 (en) * | 2001-05-08 | 2009-03-18 | 東レ株式会社 | Sepsis treatment |
MY131170A (en) * | 2002-03-28 | 2007-07-31 | Nissan Chemical Ind Ltd | Therapeutic agent for glomerular disease |
US20030195167A1 (en) * | 2002-04-15 | 2003-10-16 | Kowa Co., Ltd. | PTX3-gene expression inhibitor |
SI21402A (en) | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Lined particles and pharmaceutical forms |
AU2004233691B2 (en) | 2003-04-28 | 2007-09-20 | Sankyo Company, Limited | Sugar intake-ability enhancer |
AU2004233693B2 (en) | 2003-04-28 | 2007-07-19 | Funahashi, Toru | Adiponectin production enhancer |
GB0415789D0 (en) * | 2004-07-15 | 2004-08-18 | Astrazeneca Ab | Novel combination |
CA2573969C (en) | 2004-07-16 | 2014-02-04 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
GB0510207D0 (en) * | 2005-05-19 | 2005-06-22 | Astrazeneca Ab | Novel combination |
UA106422C2 (en) | 2006-07-05 | 2014-08-26 | Такеда Гмбх | Combined use of a pde4 inhibitor with a hmg-coa reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease |
TWI465244B (en) * | 2010-12-24 | 2014-12-21 | Ind Tech Res Inst | Use of extracts of anisomeles indica, ovatodiolide and anisomelic acid in manufacturing a medicament for preventing or treating gout |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (en) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
CA2124086A1 (en) * | 1991-11-22 | 1993-05-27 | Ronald H. Lane | Tocotrienols and tocotrienol-like compounds and methods for their use |
WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
CA2299397A1 (en) * | 1997-12-12 | 1999-06-24 | Warner-Lambert Company | Antihyperlipidemic statin-lp(a) inhibitor combinations |
-
2001
- 2001-02-08 CA CA002399396A patent/CA2399396A1/en not_active Abandoned
- 2001-02-08 US US10/203,292 patent/US20030018040A1/en not_active Abandoned
- 2001-02-08 WO PCT/JP2001/000881 patent/WO2001058443A1/en not_active Application Discontinuation
- 2001-02-08 AU AU2001232245A patent/AU2001232245A1/en not_active Abandoned
- 2001-02-08 EP EP01904345A patent/EP1275388A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1275388A1 (en) | 2003-01-15 |
US20030018040A1 (en) | 2003-01-23 |
CA2399396A1 (en) | 2001-08-16 |
WO2001058443A1 (en) | 2001-08-16 |
EP1275388A4 (en) | 2003-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001234088A1 (en) | TNF-alpha inhibitors | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU3408801A (en) | Tnf-alpha inhibitors | |
AU2002219555A1 (en) | VLA-4 Inhibitors | |
AU2001244399A1 (en) | Gamma-secretase inhibitors | |
AU2001237041A1 (en) | Kinase inhibitors | |
AU2001260674A1 (en) | TNF-alpha production inhibitors | |
AU2001296961A1 (en) | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors | |
AU4882101A (en) | Mmp-12 inhibitors | |
AU2002211663A1 (en) | Nf-$g(k)b inhibitors | |
AU2001285750A1 (en) | Urokinase inhibitors | |
AU5248800A (en) | Fading inhibitors | |
AU2001247589A1 (en) | Non-amidine containing protease inhibitors | |
AU2001294557A1 (en) | Thrombin inhibitors | |
AU2001236052A1 (en) | Urease inhibitors | |
AU2002211662A1 (en) | Nf-kappab inhibitors | |
AU2002222627A1 (en) | Tak1 inhibitors | |
AU2001255090A1 (en) | Cdk inhibitors having 3-hydroxychromen-4-one structure | |
AU2001244562A1 (en) | Neovascularization inhibitors | |
AU2001232245A1 (en) | Tnf- alpha inhibitors | |
AU3235100A (en) | Prothease inhibitors | |
AU2002224550A1 (en) | Corrosion inhibitors | |
AU1588901A (en) | Protease inhibitors | |
AU2001220281A1 (en) | Rollerboard for road-skiing | |
AU1474801A (en) | Protease inhibitors |